Literature DB >> 26434815

Survivin as a Potential Target for Cancer Therapy.

Elaheh Soleimanpour1, Esmaeil Babaei.   

Abstract

In 1997 for the first time, survivin was described by Amborsini et al. as an anti-apoptotic protein. Subsequent studies revealed that survivin is a multifunctional protein that plays critical roles in several crucial cell processes such as apoptosis, cell cycle, chromosome movement, mitosis and cellular stress responses. Moreover, it's over- expression in cancer cells versus normal cells is associated with chemotherapy resistance, increased tumor recurrence, and shorter patient survival. All of these features make survivin a promising target for cancer therapy. Here, we review the potential characteristics of survivin as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26434815     DOI: 10.7314/apjcp.2015.16.15.6187

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  14 in total

Review 1.  Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.

Authors:  Elisa Barone; Federica Gemignani; Stefano Landi
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 2.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu
Journal:  Pharmacol Ther       Date:  2016-01-22       Impact factor: 12.310

3.  Exploring the Cytotoxic Effects of the Extracts and Bioactive Triterpenoids from Dillenia indica against Oral Squamous Cell Carcinoma: A Scientific Interpretation and Validation of Indigenous Knowledge.

Authors:  Maniyamma Aswathy; Kishore Banik; Dey Parama; Parameswaran Sasikumar; Choudhary Harsha; Anuja Gracy Joseph; Daisy R Sherin; Manojkumar K Thanathu; Ajaikumar B Kunnumakkara; Radhakrishnan Kokkuvayil Vasu
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-09

Review 4.  Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins.

Authors:  Darren Finlay; Peter Teriete; Mitchell Vamos; Nicholas D P Cosford; Kristiina Vuori
Journal:  F1000Res       Date:  2017-04-27

5.  Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

Authors:  Liang Duan; Xuefei Hu; Yuxing Jin; Ruijun Liu; Qingjun You
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

6.  Evaluation of survivin expression in prostate specimens of patients with prostate adenocarcinoma and benign prostate hyperplasia underwent transurethral resection of the prostate or prostatectomy.

Authors:  Mansooreh Eslami; Tahere Khamechian; Tahere Mazoochi; Hasan Ehteram; Mojtaba Sehat; Javad Alizargar
Journal:  Springerplus       Date:  2016-05-14

7.  Intron-specific shRNA-mediated downregulation of survivin and promotion of apoptosis in HeLa cells.

Authors:  Yue-Li Wang; Xin Shao; Fa Wang; Liang Zeng; Liang Hu; Shi-Quan Cui; Gan Hou; Di-Nan Huang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

8.  XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis.

Authors:  Azhar R Hussain; Abdul Khalid Siraj; Maqbool Ahmed; Rong Bu; Poyil Pratheeshkumar; Alanood M Alrashed; Zeeshan Qadri; Dahish Ajarim; Fouad Al-Dayel; Shaham Beg; Khawla S Al-Kuraya
Journal:  BMC Cancer       Date:  2017-09-11       Impact factor: 4.430

9.  Effects and mechanism of STAT3 silencing on the growth and apoptosis of colorectal cancer cells.

Authors:  Jing Li; You-Yu Liu; Xue-Feng Yang; Dao-Fu Shen; Hong-Zhi Sun; Ke-Qiang Huang; Hua-Chuan Zheng
Journal:  Oncol Lett       Date:  2018-08-29       Impact factor: 2.967

10.  Sanguinarine Induces Apoptosis Pathway in Multiple Myeloma Cell Lines via Inhibition of the JaK2/STAT3 Signaling.

Authors:  Sabah Akhtar; Iman W Achkar; Kodappully S Siveen; Shilpa Kuttikrishnan; Kirti S Prabhu; Abdul Q Khan; Eiman I Ahmed; Fairooz Sahir; Jayakumar Jerobin; Afsheen Raza; Maysaloun Merhi; Hesham M Elsabah; Ruba Taha; Halima El Omri; Hatem Zayed; Said Dermime; Martin Steinhoff; Shahab Uddin
Journal:  Front Oncol       Date:  2019-04-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.